Surrozen Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
51.7%projected annual EPS growth
Analyst Coverage
4analysts covering
FY EPS (est.)
-$3.70next fiscal year
Monitoring Framework
Key Performance Indicators
Cash and Cash Equivalents Quarterly106.9MTarget: Sufficient to fund operations through key clinical milestones
SZN-8141 IND Submission Progress AnnuallyTarget: IND submission to FDA in H2 2026
Watch Items
- SZN-8141 IND Clearance and Phase 1 InitiationTrigger: FDA clearance of the IND applicationAction: Triggers the second tranche of the private placement worth $105 million to fund Phase 1 safety and efficacy studies.
- Merck's Restoret (Wnt agonist) Phase 2b/3 DME Data ReleaseTrigger: Data readout expected in September 2026Action: Evaluate clinical validation of the Wnt pathway mechanism in diabetic macular edema (DME) to assess competitive positioning.
- Boehringer Ingelheim Partnership Milestones for SZN-413Trigger: Successful progression of SZN-413 through IND-enabling developmentAction: Monitor for potential future milestone payments of up to $586.5 million.
Research as of 24 Jul 2026